$716.68
0.31% yesterday
Nasdaq, Dec 26, 10:04 pm CET
ISIN
US75886F1075
Symbol
REGN
Sector
Industry

Regeneron Pharmaceuticals Stock price

$716.68
-36.35 4.83% 1M
-352.48 32.97% 6M
-161.61 18.40% YTD
-132.85 15.64% 1Y
+81.91 12.90% 3Y
+341.82 91.19% 5Y
+303.20 73.33% 10Y
Nasdaq, Closing price Thu, Dec 26 2024
+2.21 0.31%
ISIN
US75886F1075
Symbol
REGN
Sector
Industry

Key metrics

Market capitalization $78.76b
Enterprise Value $71.66b
P/E (TTM) P/E ratio 17.73
EV/FCF (TTM) EV/FCF 20.83
EV/Sales (TTM) EV/Sales 5.18
P/S ratio (TTM) P/S ratio 5.69
P/B ratio (TTM) P/B ratio 2.69
Revenue growth (TTM) Revenue growth 5.72%
Revenue (TTM) Revenue $13.85b
EBIT (operating result TTM) EBIT $4.14b
Free Cash Flow (TTM) Free Cash Flow $3.44b
Cash position $9.80b
EPS (TTM) EPS $40.41
P/E forward 18.27
P/S forward 5.55
EV/Sales forward 5.05
Short interest 1.73%
Show more

Create a Free Account to create an Regeneron Pharmaceuticals alert.

Set up alerts on Stock Price, Dividend Yield, Valuation (e.g. P/E or EV/Sales) or Strategy Scores and sit back and relax.

Regeneron Pharmaceuticals Stock Analysis

Analyst Opinions

28 Analysts have issued a Regeneron Pharmaceuticals forecast:

19x Buy
68%
8x Hold
29%
1x Sell
4%

Analyst Opinions

28 Analysts have issued a Regeneron Pharmaceuticals forecast:

Buy
68%
Hold
29%
Sell
4%

Financial data from Regeneron Pharmaceuticals

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Sep '24
+/-
%
13,847 13,847
6% 6%
100%
- Direct Costs 2,391 2,391
13% 13%
17%
11,456 11,456
4% 4%
83%
- Selling and Administrative Expenses 2,435 2,435
14% 14%
18%
- Research and Development Expense 4,414 4,414
13% 13%
32%
4,608 4,608
7% 7%
33%
- Depreciation and Amortization 470 470
15% 15%
3%
EBIT (Operating Income) EBIT 4,138 4,138
9% 9%
30%
Net Profit 4,655 4,655
17% 17%
34%

In millions USD.

Don't miss a Thing! We will send you all news about Regeneron Pharmaceuticals directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Regeneron Pharmaceuticals Stock News

Neutral
GlobeNewsWire
8 days ago
Investigational REGN7508 (catalytic domain) and REGN9933 (A2 domain) are being evaluated for their potential to control thrombosis while minimizing bleeding risk in a variety of patient populations and clinical settings
Neutral
GlobeNewsWire
9 days ago
TARRYTOWN, N.Y., Dec. 17, 2024 (GLOBE NEWSWIRE) -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) will webcast its presentation at the 43rd Annual J.P. Morgan Healthcare Conference on Monday, January 13, 2025. The presentation is scheduled for 2:15 p.m. Pacific Time (5:15 p.m. Eastern Time) and may be accessed from the "Investors & Media" page of Regeneron's website at http://investor.regeneron...
Neutral
GlobeNewsWire
10 days ago
TARRYTOWN, N.Y., Dec. 16, 2024 (GLOBE NEWSWIRE) -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced its sixth consecutive inclusion in the Dow Jones Sustainability World Index (DJSI World) and fifth consecutive inclusion in the Dow Jones Sustainability North America Index (DJSI North America). These rankings highlight the company's leadership in adopting responsible practices that...
More Regeneron Pharmaceuticals News

Company Profile

Regeneron Pharmaceuticals, Inc. is a biotechnology company, which engages in the discovery, invention, development, manufacture, and commercialization of medicines. It product portfolio includes the following brands: EYLEA, Dupixent, Praluent, Kevzara, Libtayo, ARCALYST, and ZALTRAP. The company was founded by Alferd G. Gilman, Leonard S. Schleifer, and Eric M. Shooter on January 8, 1988 and is headquartered in Tarrytown, NY.

Head office United States
CEO Leonard Schleifer
Employees 13,450
Founded 1988
Website www.regeneron.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today